Tag: BAK

Upside

– $XNCR +32% (Phase 1 XmAb819 kidney-cancer data showed a 45.5% confirmed response rate and 82% six-month PFS at the proposed Phase 3 dose)

– $RENT +30% (no clear fresh catalyst identified; unusually heavy premarket volume extends Friday’s surge)

– $SGRY +24% (report of late-stage talks for Bon Secours Mercy Health to acquire a controlling stake at about $20 a share)

– $RRC +11% (EQT agreed to acquire it in a 0.987-share all-stock deal)

– $MACI +10% (shareholders approved the Everli business combination)

– $ROST +3.4% (UBS upgrades to Buy)

– $AVBP +3.3% (initial Phase 1 ARR-217 data showed a 44.8% response rate in colorectal cancer at the selected dose)

– $TSLA +2.3% (Barclays upgrades to Overweight, citing improving auto fundamentals, robotaxi momentum and potential SpaceX-combination upside)

Downside

– $XP -48%, $STNE -39%, $PAGS -32%, $BBD -30%, $ITUB -26%, $NU -26% (Brazil-linked financials plunge after leftist incumbent Lula won the presidential election over Flávio Bolsonaro)

– $BAK -34%, $PBR -19%, $VALE -4.9% (Brazil commodity names fall on the election shock and policy-risk repricing)

– $MRNA -8.1% (sell-the-news unwind continues after Phase 3 melanoma-vaccine data, with expectations elevated following the prior rally)

– $EQT -6.8% (falls as the acquirer in the all-stock purchase of RRC)

– $EFX -3.5% (RBC downgrades to Sector Perform on mortgage weakness concerns)

– $NTAP 3.0% (Guggenheim initiates coverage at Neutral)

– $CRWV -2.2%, $IREN -2.0% (neoclouds fall after SpaceX closed a $40B debt raise to buy Nvidia GPUs, signaling a large captive AI-compute build)